MDWD (MediWound Ltd.) Stock | Pipeline, Insider Trades & Financials

Recently added Catalysts

Upcoming Catalyst

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Options Data

News Section

Hedge Funds

Ownership Trends

Competitive Position

MediWound Ltd.

$14.22

+0.13 (+0.92%)

D 38Pipeline Score Overvalued Pharma · Clinical

Market Cap

212.98 M

EPS

-2.10

P/E Ratio

Value Trade

2.26 M

-0.06 %

Week

-0.72 %

1 Month

-4.16 %

3 Month

-3.38 %

6 Month

-35.09 %

5 Year

-85.19 %

All Time

Cash Data

Cash Position
12.35 K
Monthly Burn
12.35 K
Runway
12,345 mo

Overview

Volume

48.05 K

52 Week Range

14.90 - 22.51

% held by Insiders

25.52 %

% held by Institutions

55.74 %

Enterprise Value

168.62 M

Total Shares

12.81 M

Short %

16.96 %

Float Shares

9.59 M

Company Description

Employees:121

https://www.mediwound.com

locked

Upcoming Catalyst

Catalyst	Drug/Treatment	Stage	Probability of Approval	Description	Drug Type	Therapeutic Area
Interim results example	EscharEx® Venous leg ulcers (VLUs)	Phase 3	—	Subscribe to access the data.	Enzyme Replacement Therapies (ERT)	Dermatologic System
Interim results example	EscharEx® Venous leg ulcers (VLUs)	Phase 3	—	Subscribe to access the data.	Enzyme Replacement Therapies (ERT)	Dermatologic System
Interim results example	EscharEx® Venous leg ulcers (VLUs)	Phase 3	—	Subscribe to access the data.	Enzyme Replacement Therapies (ERT)	Dermatologic System

Unlock Upcoming Catalyst data

Drug Pipeline Intelligence

D38

Pipeline Score

$83M

Pipeline Value

Overvalued

Valuation Signal

Drugs Scored

0.4x

rNPV / MCap

Top 48%

Micro Cap

(rank 472 of 905)

Percentile Rank

MediWound Ltd. faces pipeline headwinds (38/100), with $569M risk-adjusted pipeline value, led by EscharEx in Venous Leg Ulcer (VLU) (Phase 3).

Showing 1 of 1 assets

Drug	Indication	Phase	NCT ID	PTRS	rNPV	Status	Enrollment	Velocity	Design	Completion	ML Signal	Last Change
EscharEx Small molecule	Venous Leg Ulcer (VLU)	Phase 3	NCT06568627	55%	$260M	RECRUITING	216	AVERAGE	B (75)	Mar 1, 2027	LOW_RISK	LOW May 26, 2026

Unlock Drug Pipeline Intelligence

Clinical Trial Results

Drug Name	Indications	Phase	Date	Trial Results Summary	Title
EscharEx	chronic venous leg ulcers	Phase 2	2025-08-14	Wounds that failed to achieve WBP had a 90% probability of not healing (Negative Predictive Value = 90%),Wounds that achieved WBP were 4.1 times more likely to close compared to those that did not (p = 0.0004),Early achievement of WBP (within 14 days) was associated with a significantly increased likelihood of healing (Relative Risk = 2.4, p = 0.0005),Wounds that failed to reach WBP had a 12-fold higher risk of remaining unhealed throughout the study period (Hazard Ratio = 12, p < 0.0001)	MediWound Announces New EscharEx® Phase II Data Demonstrating Strong Link Between Wound Bed Preparation and Wound Closure in Venous Leg Ulcers Read More
EscharEx	chronic venous leg ulcers	Phase 2	2025-08-14	Wounds that failed to achieve WBP had a 90% probability of not healing (Negative Predictive Value = 90%),Wounds that achieved WBP were 4.1 times more likely to close compared to those that did not (p = 0.0004),Early achievement of WBP (within 14 days) was associated with a significantly increased likelihood of healing (Relative Risk = 2.4, p = 0.0005),Wounds that failed to reach WBP had a 12-fold higher risk of remaining unhealed throughout the study period (Hazard Ratio = 12, p < 0.0001)	MediWound Announces New EscharEx® Phase II Data Demonstrating Strong Link Between Wound Bed Preparation and Wound Closure in Venous Leg Ulcers Read More
EscharEx	chronic venous leg ulcers	Phase 2	2025-08-14	Wounds that failed to achieve WBP had a 90% probability of not healing (Negative Predictive Value = 90%),Wounds that achieved WBP were 4.1 times more likely to close compared to those that did not (p = 0.0004),Early achievement of WBP (within 14 days) was associated with a significantly increased likelihood of healing (Relative Risk = 2.4, p = 0.0005),Wounds that failed to reach WBP had a 12-fold higher risk of remaining unhealed throughout the study period (Hazard Ratio = 12, p < 0.0001)	MediWound Announces New EscharEx® Phase II Data Demonstrating Strong Link Between Wound Bed Preparation and Wound Closure in Venous Leg Ulcers Read More

Unlock Clinical Trial Results data

Inside Trades

YEARLY INSIDER TRANSACTIONS

Sector Avg.

INSIDERS
SOLDINSIDERS
BOUGHT

POSITIVE SENTIMENT Based on 22 Insiders Transactions

Unlock Inside Trades data

Show Data

Hedge Funds

Shares Held

2040.00B1530.00B1020.00B510.00B0

Q3
2024

Q4
2024

Q1
2025

Q2
2025

HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT

POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter

18 buying (3 new)·9 selling (1 exited)·2 unchanged

Fund Count

60%

Share Volume

25%

Conviction

15%

Hedge Funds invested in MDWD

HedgeFund Name ( 3 )	% of Portfolio	Current MV -	Shares Owned -
Example Capital Management	2.5 %	15.00 M	250.00 K
Example Capital Management	2.5 %	15.00 M	250.00 K
Example Capital Management	2.5 %	15.00 M	250.00 K

Unlock Hedge Funds table data

Biotech Analyst Ratings

Symbol

Firm

Rating

Action

Price Target

Upside

date

MDWD

Example Securities

Buy

Initiated

$150.00

+25%

2026-01-15

MDWD

Example Securities

Buy

Initiated

$150.00

+25%

2026-01-15

MDWD

Example Securities

Buy

Initiated

$150.00

+25%

2026-01-15

Unlock Biotech Analyst Ratings data

MDWD Stock Forecast & Analyst Consensus

BUY

Analyst Ratings

Buy65.0%

Hold25.0%

Sell10.0%

Price Target Trend

Average$24.00

Low$18.00

High$32.00

Unlock Price Target Trend

MDWD Institutional Ownership Trends

Current Insider %

5.20%

—+0.00%

Current Institutional %

62.40%

—+0.00%

Total Ownership

67.60%

Insider + Institutional

Data Points

1 Ticker(s)

Option Chain Statistics

Expiration	Volume			Open Interest			Implied Volatility Calls			Implied Volatility Puts
Expiration	Calls	Puts	Put-Call Ratio	Calls	Puts	Put-Call Ratio	IV	OiWaIv	VWaIv	IV	OiWaIv	VWaIv
2026-06-18			0.00			0	-	-	-	-	-	-
2026-06-18			0.00			0	-	-	-	-	-	-
2026-06-18			0.00			0	-	-	-	-	-	-

Unlock Option Chain Statistics data

Option Chain

Calls			Strike	Puts
Last Price	Volume	Open Interest	Strike	Last Price	Volume	Open Interest
No data available

Unlock Option Chain data

Unlock Options Chart data

Open interest

Today's Open Interest

1.00 M

Put-Call Ratio

1.1

Put Open Interest

480.00 K

Call Open Interest

520.00 K

Open Interest Avg (30-day)

900,000

Today vs Open Interest Avg (30-day)

11.11%

Option Volume

Today's Volume

750.00 K

Put-Call Ratio

0.95

Put Volume

360.00 K

Call Volume

390.00 K

Volume Avg (30-day)

800,000

Today vs Volume Avg (30-day)

-6.25%

Latest MediWound Ltd. (MDWD) News & Alerts

Saturday, June 13, 2026

(%)

+ More

Demo Biotech Announces Positive Phase 3 Results

Competitive Position

How MDWD ranks across every disease it competes in

Show observational/device entries

Indication	Rank	Phase	Best Drug	Top 3 Competitors	Market $B	LoA	Position
Skin Ulcers	#1 of 3	PHASE 2	EscharEx	ORGO SKYE	—	0.95	LEADER
Skin Cancer	#2 of 4	PHASE 1	EscharEx 5%	REPL NVS REGN	$18.7B	0.97	CONTENDER

Recent Updates

Recently added Catalysts

$14.22

Cash Data

Overview

Company Description

Upcoming Catalyst

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Hedge Funds

Hedge Funds invested in MDWD

Biotech Analyst Ratings

MDWD Stock Forecast & Analyst Consensus

MDWD Institutional Ownership Trends

Option Chain Statistics

Option Chain

Open interest

Option Volume

Latest MediWound Ltd. (MDWD) News & Alerts

Demo Biotech Announces Positive Phase 3 Results

Competitive Position

Indication landscape

FDA Calendar

BPW Portfolio

Historical FDA Calendar

Market Movers

Biotech Earning Calendar

Historical PDUFA Dates

PDUFA Calendar

Conference Calendar

IPO

Catalyst Sync™

Hedge Fund Screener

Company Screener

All Stocks Holdings

Heat-Map

Inside Trades

Biotech Analyst Ratings

M&A Tracker

News

Blogs

Modality Leaderboard

Discord

User Guide

Biotech Investing 101

Recent Updates

Recently added Catalysts

$14.22

Cash Data

Overview

Company Description

Upcoming Catalyst

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Hedge Funds

Hedge Funds invested in MDWD

Biotech Analyst Ratings

MDWD Stock Forecast & Analyst Consensus

MDWD Institutional Ownership Trends

Option Chain Statistics

Option Chain

Open interest

Option Volume

Latest MediWound Ltd. (MDWD) News & Alerts

Demo Biotech Announces Positive Phase 3 Results

Competitive Position